Childs Nerv Syst. 2017 May 3. doi: 10.1007/s00381-017-3431-0. [Epub ahead of print]

Green AL1,2, Mulcahy Levy JM3,4, Vibhakar R3,4, Hemenway M3,4, Madden J3,4, Foreman N3,4, Dorris K3,4.

 

Author information:

1

    Program in Neuro-Oncology, Center for Cancer and Blood Disorders, Children's Hospital Colorado, 12800 E. 19th Ave. RC1-N, Mail Stop 8302, Aurora, CO, 80045, USA. adam.green@ucdenver.edu.

2

    Morgan Adams Foundation Pediatric Brain Tumor Research Program, Department of Pediatrics, School of Medicine, University of Colorado Anschutz Medical Campus, 12800 E. 19th Ave. RC1-N, Mail Stop 8302, Aurora, CO, 80045, USA. adam.green@ucdenver.edu.

3

    Program in Neuro-Oncology, Center for Cancer and Blood Disorders, Children's Hospital Colorado, 12800 E. 19th Ave. RC1-N, Mail Stop 8302, Aurora, CO, 80045, USA.

4

    Morgan Adams Foundation Pediatric Brain Tumor Research Program, Department of Pediatrics, School of Medicine, University of Colorado Anschutz Medical Campus, 12800 E. 19th Ave. RC1-N, Mail Stop 8302, Aurora, CO, 80045, USA.

 

Abstract

PURPOSE:

 

Tumor treating fields (TTF) are alternating electric fields applied continuously to the scalp. The treatment is approved for both primary and recurrent supratentorial adult glioblastoma but unstudied in children.

METHODS:

 

We report a feasibility case series of five pediatric high-grade glioma patients (ages 10-20 years) treated at our institution with TTF along with chemotherapy and/or radiation.

RESULTS:

 

Two patients began therapy at second recurrence and showed progressive disease. Two others were treated upfront after radiation therapy, and both showed partial responses. A fifth patient was treated at first recurrence and also showed a partial response. All five tolerated TTF well without treatment-limiting toxicities.

CONCLUSIONS:

 

The tolerability of TTF, combined with the adult data, justify a pediatric clinical trial.

PMID: 28470383